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Several uncertainties surround optimal management of colorectal cancer. We investigated treatment patterns and factors influencing
treatment receipt and mortality in routine clinical practice. We included 15249 individuals, recorded by the National Cancer Registry
(Ireland), with primary invasive colon or rectal tumours, diagnosed during 1994–2002. Logistic regression and Cox proportional
hazards were used to determine factors associated with treatment receipt within 1 year of diagnosis and with mortality, respectively.
A total of 78% had colorectal resection, 31% chemotherapy, and 13% radiotherapy (4% colon; 28% rectum). Half of stage IV patients
underwent resection. Chemotherapy and radiotherapy use increased by at least 10% per annum. There was a notable increase in
pre-operative radiotherapy from 2000 onwards. Patient-related factors were significantly associated with treatment receipt. Patients
who were male, older, not married, or smokers had significantly higher risks of death. Chemotherapy was significantly associated with
lower mortality for stage III, but not stage II, colon cancer. For rectal cancer, pre-operative radiotherapy was associated with reduced
mortality. Surgery and chemotherapy were associated with longer survival for stage IV patients. The observed inequities in treatment
and outcomes suggest that there is potential for further dissemination of therapies in routine practice. Improving treatment availability
overall, and equity, has the potential to reduce mortality.
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Colorectal cancer is responsible for more than half a million deaths
worldwide each year (Ferlay et al, 2004). In many developed
countries, mortality rates have been falling for 20–30 years
(Coleman et al, 1993), reflecting steady improvements in survival
(Verdecchia et al, 2007). However, there remains considerable
international variation in survival even between developed nations;
5-year relative survival for patients in the USA is around 65%,
whereas that within Europe ranges between 45 and 64%
(Verdecchia et al, 2007). Differences in stage at diagnosis, although
important (Gatta et al, 2000; Ciccolallo et al, 2005), do not
completely explain survival inequalities. Variations in treatment
use and quality may also play a role.
Several uncertainties surround optimal colorectal cancer
therapy, and this is reflected in variations in best-practice
guidelines. Although surgery is the cornerstone of treatment for
apparently localized disease, international variations have been
reported in resection rates (Ciccolallo et al, 2005). For locally
advanced or metastatic disease, there is no consensus on when
excision of the primary tumour should be attempted (SIGN, 2003;
NCCN, 2006a,b). Use of adjuvant therapy depends both on site
and stage. For example, adjuvant chemotherapy is not routinely
recommended for stage II colon cancer (SIGN, 2003; Australian
Cancer Network Colorectal Cancer Guidelines Revision Committee,
2005) given the inconclusive findings from randomised controlled
trials (RCTs) (Mamounas et al, 1999; Benson et al, 2004). However,
some recent studies suggest that stage II patients with poor
prognostic features (such as bowel perforation, involved lymph
nodes, etc.) might benefit (Gill et al, 2004; Andre ´ et al, 2006) and
US and Australian guidelines advocate chemotherapy for this
subgroup (Australian Cancer Network Colorectal Cancer Guide-
lines Revision Committee, 2005; NCCN, 2006a). For stage III colon
cancer, RCTs suggest that best practice is surgery followed by
chemotherapy (5-fluorouracil (5-FU)–leucovorin or capecitabine,
and more recently supplementation with oxaliplatin) to improve
survival (Cascinu et al, 2003; Andre ´ et al, 2004a; Twelves et al,
2005). In advanced disease, irinotecan or oxaliplatin with 5-FU is
recommended for primary therapy (NICE, 2005). For rectal cancer,
until recently post-operative radiotherapy was the standard of care
for locally advanced disease, but RCTs have indicated that
pre-operative administration may improve local control, with
lower toxicity and reduced rectal cancer deaths (Colorectal Cancer
Collaborative Group, 2001; Sauer et al, 2004). The addition of
chemotherapy improves response and is recommended (SIGN,
2003; Australian Cancer Network Colorectal Cancer Guidelines
Revision Committee, 2005).
How these uncertainties and complexities translate into routine
clinical practice is not clear. Some studies have suggested that
(neo-) adjuvant therapies may be under-utilized and that use
depends on patient characteristics such as age or ethnicity (Schrag
et al, 2001a,b; Potosky et al, 2002; Martijn et al, 2003; Cronin et al, Revised 1 May 2008; accepted 27 May 2008; published online 1 July 2008
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s2006). However, most population-based studies originate from the
United States, relate to patients diagnosed in the first half of the
1990s, and/or focus on patient subgroups (e.g. stage III disease).
We therefore undertook a population-based investigation of trends
in treatment and factors predicting treatment receipt, survival, and
mortality for patients with all stages of disease during 1994–2002
in Ireland – a country with relatively high colorectal cancer
mortality (Ferlay et al, 2004).
MATERIALS AND METHODS
Details of individuals aged X20 with invasive colorectal cancer
(ICD-02: C18-20) diagnosed during 1994–2002 were abstracted
from the National Cancer Registry (NCR), which records all cancers
diagnosed in Ireland (www.ncri.ie). Completeness of registration is
approximately 98% (NCR, 2001). Cases were excluded where
diagnosis was made by death certificate only or at autopsy, or the
tumour was a secondary malignancy (other than non-melanoma
skin), or occurred simultaneously with another tumour.
Using information on treatments administered within 1 year of
diagnosis, cases were categorised by receipt of (1) ‘cancer-directed’
surgery (i.e. colon or rectal resection), (2) chemotherapy, or (3)
radiotherapy. Chemotherapy and radiotherapy were classified as
‘any’, ‘pre-operative’, or ‘post-operative’ based on dates of surgery
and the start of the first treatment course. Stage was defined by
AJCC summary staging (AJCC, 2002), making the assumption that
patients with no information on distant metastasis (MX) had no
metastasis (M0). Dates and causes of death were ascertained by
linkage to death certificates. Patients were followed up from date of
diagnosis to death or 31 December 2004, whichever was sooner.
Associations between patient characteristics and stage were
evaluated using w
2 tests. Temporal trends in treatment were
explored by jointpoint regression (Edwards et al, 2005). Multi-
variate logistic regression models, stratified by stage, were built to
identify factors associated with treatment receipt. For surgery, only
stage IV and unstaged patients were modelled, as almost all stage
I–III patients had resection. For chemotherapy and radiotherapy,
stage I patients were excluded as few received these therapies.
Models were adjusted for sex and factors significant (Po0.10) on
likelihood ratio tests. Factors considered for inclusion were age,
marital status, site, grade, tumour extent (T), regional lymph node
status (N) (as within a given stage, subgroups of patients might
receive adjuvant therapy), year of diagnosis, smoking status at
diagnosis, and health board of residence (as cancer services were
organised at this level in 1994–2002). Model goodness of fit was
assessed by the Hosmer–Lemeshow test. Multivariate Cox
proportional hazard models were run for all-cause and colorectal
cancer-specific mortality. As results were similar, only all-cause
mortality is presented. Surgical and non-surgical patients were
modelled separately and covariates included if significant
(Po0.10) on Wald F-tests. Owing to non-proportional hazards,
chemotherapy and radiotherapy were included as time-varying
covariates with date of the start of the first course as the index
date. In all models we tested for interactions between variables; any
that were meaningful, statistically significant, and impacted on risk
estimates were included in the final models. Kaplan–Meier curves,
adjusted for age, were constructed to illustrate the impact of
treatment on survival time.
RESULTS
Colon cancer accounted for 63% of the 15249 patients included.
Overall, 57% were male (53% of colon, 64% of rectal tumours) and
92% had histologically verified disease. Less than 12% were stage I,
25% were stage II, 23% were stage III, 22% were stage IV, and 17%
were unknown stage. Unstaged patients were older and more often
had rectal tumours. Stage distribution changed relatively little over
time (stage I/II: 39% in 1994–96 and 36% in 2000–02; stage III/IV:
43 and 48%; unstaged: 18 and 15%).
Treatment rates and trends over time
Overall, 78% of patients had surgical resection, 31% chemo-
therapy, and 13% radiotherapy, the latter primarily for rectal
cancer (28% rectal, 4% colon; Table 1). Almost all stage I–III
patients (96%) had surgery, compared with 51% with stage IV and
47% with unknown stage. Chemotherapy and radiotherapy were
used almost exclusively among surgical patients. For rectal cancer,
both therapies were more often used post-operatively (chemo-
therapy 31%, radiotherapy 16%) than pre-operatively (6 and 8%,
respectively). Overall, 17% of patients received no cancer-directed
treatment; almost all of these had stage IV (45%) or unstaged
(47%) disease.
From 1994 to 2002, there was no change in the proportion
undergoing surgery (data not shown). Chemotherapy use in-
creased significantly for both colon and rectal cancer (estimated
annual percentage change (EAPC)¼þ9.6%, 95% CI þ8.4,
þ10.8%; Figure 1A), although the increase slowed down for colon
cancer patients in 2000–02. The growth in chemotherapy was
evident for all disease stages. Use of radiotherapy for rectal cancer
increased overall (EAPC¼þ12.3%, 95% CI þ10.3, þ14.2%;
Figure 1B), particularly for those with stage I disease
(EAPC¼þ23.0%, 95% CI þ16.0, þ30.3%). The upward trend
was most pronounced for pre-operative use (EAPC¼þ34.3%,
95% CI þ24.7, þ44.6%; Figure 1C), particularly from 2000
onwards.
Factors associated with treatment receipt
With regard to surgery for stage IV disease, in multivariate
analyses, resection was significantly less common among patients
who were older, unmarried, and male (Pp0.01; data not shown)
and there was a borderline significant effect of site (multivariate
odds ratio (OR) rectum vs colon¼0.87, 95% CI 0.75–1.01). For
Table 1 Treatments administered to colorectal cancer patients
diagnosed during 1994–2002: numbers and percentages of all patients
Colon Rectum Total
Variable No. % No. % No. %
Overall treatment
a
Surgery
b 7591 79.0 4285 76.0 11876 77.9
Any chemotherapy 2807 29.2 1873 33.2 4680 30.7
Any radiotherapy 410 4.3 1578 28.0 1988 13.0
Pre-operative treatment
c
Chemotherapy 45 0.6 240 5.6 285 2.4
Radiotherapy 11 0.1 339 7.9 350 2.9
Postoperative treatment
c
Chemotherapy 2435 31.9 1336 31.0 3771 31.6
Radiotherapy 227 3.0 682 15.8 909 7.6
Treatment combinations
Surgery only
b 5000 52.0 2419 42.9 7419 48.7
Chemotherapy only 304 3.2 123 2.2 427 2.8
Radiotherapy only 41 0.4 174 3.1 215 1.4
Surgery and radiotherapy 116 1.2 302 5.4 418 2.7
Surgery and chemotherapy 2250 23.4 648 11.5 2898 19.0
Chemotherapy and radiotherapy 28 0.3 186 3.3 214 1.4
Surgery, radiotherapy,
and chemotherapy
225 2.3 916 16.3 1141 7.5
No cancer-directed treatment 1649 17.2 868 15.4 2517 16.5
aCategories not mutually exclusive; figures do not sum to 100%.
bResection of the
colon or rectum.
cPercentage of surgical patients.
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sunknown stage disease, older, unmarried patients were significantly
less likely to undergo resection (Po0.001; data not shown), as were
those with tumour extent T4 (OR¼0.07, 95% CI 0.05–0.11).
Table 2 shows factors associated with chemotherapy receipt. For
all stages, older and unmarried patients were significantly less
likely to receive chemotherapy. For stage III and IV patients, there
was a strong positive effect of year of diagnosis. For stage II and
unknown stage patients, there was year of diagnosis–site
interaction; chemotherapy use increased over time, but to a
greater extent for rectal than colon patients. Tumour extent was
associated with likelihood of chemotherapy receipt. For stage II
patients, those with T4 tumours were significantly more likely to
be treated than those with T3 tumours (multivariate OR¼1.69,
95% CI 1.33–2.15). For III, IV, and unstaged patients, those with
T3 tumours were most likely to have chemotherapy.
Table 3 shows factors associated with radiotherapy use in rectal
cancer. For all disease stages, use decreased significantly with
increasing age. Women were slightly less likely to get radiotherapy
than men, and this was significant for stage II disease. For stage III
patients, use was less common among those who were not married
(P¼0.055). Tumour extent was significantly associated with
radiotherapy receipt in patients with unknown and stage II
disease, but not stage III and IV disease. Among those with stage II
or unknown stage disease, patients with T4 tumours were more
likely to receive radiotherapy than those with other tumours.
With regard to pre-operative radiotherapy specifically, use was
significantly less frequent among female patients (multivariate
OR¼0.67, 95% CI 0.51–0.87) and decreased with age (P(trend)
o0.001; data not shown).
Survival and factors associated with mortality
Five-year observed survival was 40% overall, and 72, 59, 41, 7, and
31% for stage I, II, III, IV, and unstaged tumours, respectively. It
was 49% for surgical and 9% for non-surgical patients. Among
stage IV patients, 50% who underwent resection were alive at 1
year compared with 16% who did not.
Table 4 shows factors associated with mortality, stratified by
surgery receipt. The risk of death fell over time for surgical
patients. In both groups, men had significantly higher hazard
ratios (HR) than women, and married patients had lower hazards
(Pp0.01). The HR increased with age, particularly for older
surgical patients. Patients who presented with later stage disease
and with poorly differentiated or undifferentiated tumours had
significantly higher hazards (Pp0.01). Smokers had increased
hazards, and this reached significance among surgical patients.
Table 5 shows HRs for chemotherapy and radiotherapy receipt,
stratified by stage, and Figure 2 shows survival according to
treatment. Stage III patients who received chemotherapy had a
significantly reduced risk of death (all patients HR¼0.67, 95% CI
0.61–0.75) and higher survival (Figure 2A). No such effects were
evident for stage II disease. For stage IV disease, surgical patients
had higher survival; this was evident up to approximately 3 years
after diagnosis among the group who had surgery and up to 2
years after diagnosis among those who did not have surgery
(Figure 2B). Among surgical stage IV patients, chemotherapy
receipt was associated with a significantly reduced risk of death
(HR¼0.77, 95% CI 0.68–0.88). For rectal cancer, receipt of any
radiotherapy (pre- or post-operative) had no significant impact on
mortality for patients with any stage of disease (Table 5). However,
when the analysis was limited to patients who had surgery and
radiotherapy, those who received pre-operative, as compared with
post-operative, radiotherapy had reduced HRs. This was seen for
all stages of disease except stage II, but the reduction in the HR
reached statistical significance only for stage III disease
(HR¼0.61, 95% CI 0.42–0.91).
DISCUSSION
Strengths and limitations
This is one of the largest population-based studies of treatment
trends and factors predicting treatment receipt for colorectal
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Figure 1 Trends in treatment receipt among colorectal cancer patients,
1994–2002: observed frequencies plus jointpoint regression lines. (A)
chemotherapy (% of all patients), (B) radiotherapy (% of all patients), and
(C) pre and postoperative therapy (% of rectal cancers).
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scancer, and is one of the few studies conducted outside the USA.
We have described treatment patterns in routine clinical practice,
rather than in specialized treatment centres, and in a setting with
relatively high colorectal cancer mortality (Ferlay et al, 2004). With
regard to limitations, we did not have details of specific
chemotherapy regimens or radiotherapy courses. However,
assessment of such details was not our aim. Although we only
had information on treatments received within a year of diagnosis,
most active treatment for the primary tumour would be offered
within this time. A priori, we could not distinguish whether
treatments were given with curative or palliative intent. Stratifica-
tion of the analysis by stage and investigation of treatment
combinations helped clarify this to some extent.
For 40% of the cases information on T, N, and M status was
incomplete. The registration procedures of the National Cancer
Registry include medical record review, so these data would have
been recorded had they been available in notes. In a substantial
proportion of these cases, it is probable that the investigations to
confirm presence – or more likely absence – of metastases were not
carried out. We coded cases with missing metastasis data to no
metastasis, reducing the proportion ‘unstaged’ to 17%. The validity
of this assumption was verified by repeating the analyses after
assigning patients with missing metastasis data to the unstaged
group – our results were not altered.
Other than stage and grade, no prognostic information (e.g.
bowel perforation, number of lymph nodes examined, etc.) was
available. Such factors are likely to have determined treatment
aggressiveness and survival, especially among stage II colon cancer
patients, who comprise a particularly heterogeneous group (Andre ´
et al, 2006).
Treatment rates and trends over time
The colorectal resection rate was constant over time, in contrast to
a US study that reported a slight, but significant, decrease during
1988–2000 (Cook et al, 2005). Our frequency of 78% undergoing
resection was lower than that in US studies (90–92%; Ciccolallo
et al, 2005) but close to figures for European community practice
Table 2 Factors associated with chemotherapy receipt among colorectal cancer patients diagnosed during 1994–2002: observed and adjusted
percentages, multivariate ORs
a with 95% CIs, and P-values
Stage II (n¼3879) Stage III (n¼3553) Stage IV (n¼3308) Stage unknown (n¼2620)
obs% adj% OR (95% CI) obs% adj% OR (95% CI) obs% adj% OR (95% CI) obs% adj% OR (95% CI)
Sex
Male 30 22 1 (ref) 54 50 1 (ref) 40 32 1 (ref) 14 6 1 (ref)
Female 26 21 0.92 (0.78, 1.08) 49 52 1.06 (0.90, 1.25) 34 31 0.95 (0.79, 1.13) 11 6 0.96 (0.72, 1.26)
P¼0.308 P¼0.478 P¼0.563 P¼0.750
Age
o55 62 61 1 (ref) 79 80 1 (ref) 68 66 1 (ref) 36 29 1 (ref)
55–64 48 46 0.56 (0.44, 0.72) 72 72 0.65 (0.49, 0.85) 57 53 0.60 (0.46, 0.77) 26 19 0.59 (0.40, 0.87)
65–74 28 27 0.24 (0.19, 0.30) 55 56 0.32 (0.25, 0.42) 37 34 0.27 (0.21, 0.34) 15 10 0.27 (0.18, 0.40)
75+ 6 5 0.04 (0.03, 0.05) 19 18 0.05 (0.04, 0.07) 10 10 0.06 (0.04, 0.08) 3 2 0.05 (0.03, 0.08)
Po0.001 Po0.001 Po0.001 Po0.001
Marital status
Married 35 24 1 (ref) 62 57 1 (ref) 47 37 1 (ref) 18 7 1 (ref)
Not married/
unknown
19 18 0.69 (0.58, 0.82) 38 43 0.55 (0.47, 0.65) 26 25 0.58 (0.49, 0.70) 9 5 0.73 (0.55, 0.96)
Po0.001 Po0.001 Po0.001 P¼0.026
Year of diagnosis — 1.26 (1.22, 1.30) 1.21 (1.17, 1.25) —
Po0.001 Po0.001
Site
Colon — 49 49 1 (ref) 36 30 1 (ref) —
Rectum — 56 55 1.26 (1.07, 1.49) 41 34 1.16 (0.97, 1.39) —
P¼0.006 P¼0.100
Site year
b
Colon, 1994–96 20 14 1 (ref) — — 9 4 1 (ref)
Colon, 1997–99 29 23 1.87 (1.47, 2.38) — — 9 4 0.91 (0.56, 1.48)
Colon, 2000–02 29 25 2.08 (1.63, 2.67) — — 9 5 1.08 (0.65, 1.79)
Rectal, 1994–96 20 13 0.93 (0.66, 1.31) — — 9 4 1.02 (0.62, 1.70)
Rectal, 1997–99 34 26 2.22 (1.65, 2.99) — — 17 8 2.05 (1.31, 3.21)
Rectal, 2000–02 48 39 4.05 (3.01, 5.44) — — 25 16 4.14 (2.64, 6.48)
Po0.001 Po0.001
Tumour extent
T1 — 48 36 0.50 (0.25, 1.04) 18 16 0.34 (0.13, 0.84) 3 1 0.06 (0.03, 0.13)
T2 — 51 49 0.88 (0.68, 1.13) 39 35 1.00 (0.67, 1.49) 12 4 0.27 (0.16, 0.46)
T3 27 20 1 (ref) 52 53 1 (ref) 46 35 1 (ref) 27 15 1 (ref)
T4 36 30 1.69 (1.33, 2.15) 49 47 0.78 (0.63, 0.97) 40 31 0.84 (0.68, 1.04) 20 13 0.89 (0.59, 1.36)
Missing — 31 29 0.37 (0.14, 0.93) 24 27 0.68 (0.51, 0.90) 9 5 0.33 (0.23, 0.47)
Po0.001 P¼0.017 P¼0.020 Po0.001
Nodes
N0 — — 35 28 1 (ref) —
N1/N2 — — 52 40 1.68 (1.31, 2.15) —
Missing — — 25 26 0.87 (0.65, 1.16) —
Po0.001
CI¼confidence interval; OR¼odds ratio.
aOdds ratios adjusted for factors shown in relevant column, plus health board and grade.
bInteraction term for site and period of
diagnosis.
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s(Gatta et al, 2000; Pitchforth et al, 2002). The differences may be
partly a result of variations in stage distribution between
populations, but are more likely to be due to lack of consensus
regarding resection of the primary tumour in stage IV patients
(Rosen et al, 2000; Sarela et al, 2001; Ruo et al, 2003). In two US
population-based studies, 66% of stage IV patients of all ages
(Cook et al, 2005) and 72% of those aged X65 had primary cancer-
directed surgery (Temple et al, 2004); this was 51% in our study
overall.
One of the major reasons for examining treatment patterns in
routine clinical practice is to determine whether potential exists for
further dissemination of therapies across the patient population.
The increased use of chemotherapy and radiotherapy over time
(10 and 12% per annum, respectively) suggests some dissemina-
tion of RCT-approved therapies into community practice. The
dramatic increase in pre-operative radiotherapy for rectal cancer
from 2000 onwards is similar to recent US trends (Cronin et al,
2006). It is noteworthy, however, that post-operative radiotherapy
is still commonly used in our population, in contrast to the USA
and the Netherlands, where there has been a shift to pre-operative
administration (Martijn et al, 2003; Cronin et al, 2006). In the
Netherlands this was due to implementation of new guidelines, and
illustrates the potential for these (which do not exist in Ireland) to
influence patient management in routine practice.
Use of chemotherapy was slightly lower in our population than
in US community practice (Jessup et al, 2005; Cronin et al, 2006).
This was particularly true for older patients: 38% of stage III
patients over 65 in Ireland had chemotherapy compared with 55%
in the United States in 1991–96 (Schrag et al, 2001a). Similarly,
only 24% of over 65 with stage IV disease had chemotherapy
compared with 44% in the United States in 1991–99 (Temple et al,
2004). Somewhat more reassuringly, when compared with other
European population-based series from the 1990s, utilization of
chemotherapy in our population did not appear to be unusually
low (Bouchardy et al, 2001; Faivre-Finn et al, 2002). For rectal
cancer, however, radiotherapy use was low compared to both US
and European populations (28% in Ireland vs 46–62% elsewhere)
(Ayanian et al, 2003; Cronin et al, 2006; Vulto et al, 2007). Possible
reasons for this include a lack of guidelines, lack of centralisation
and specialisation of cancer services during the study period, and a
shortfall in radiation oncology services (Expert Working Group on
Radiation Oncology Services, 2003).
In our study, 17% of patients did not receive any cancer-directed
treatment. This group comprised mainly elderly patients who
presented late and for whom treatment options were likely to be
limited. Almost 60% were 75 or older at diagnosis and a further
27% were 65–74 years; 45% were stage IV and 47% had unknown
stage disease. The median survival of the entire group was only 2
months. Whether this might have been longer had some of these
individuals received treatment (e.g. by irinotecan or oxaliplatin
with 5-FU; NICE, 2005) is open to speculation.
Factors associated with treatment
As only 4% of stage I–III cases did not have surgery, we were
unable to investigate factors associated with not undergoing
resection for these patients. For stage IV disease, the likelihood of
colorectal resection declined with increasing age. This was also
observed in two US series (Temple et al, 2004; Cook et al, 2005),
although in both series the effect was mainly limited to the very old
(80 or 85 and over), whereas in our study there was a steady
decrease with increasing age (60% of the under 65s had a resection,
whereas only 51% aged 65–74 and 42% aged X75 did). In addition
to having more co-morbid conditions (Yancik et al, 1998), older
patients are more likely to require emergency surgery (Colorectal
Cancer Collaborative Group, 2000a), and these factors may
influence the proportion resected in different populations. We
also found that female, stage IV patients were significantly more
likely to undergo resection, which has not been seen elsewhere.
Table 3 Factors associated with radiotherapy receipt among rectal cancer patients diagnosed during 1994–2002: observed and adjusted percentages,
multivariate ORs
a with 95% CIs, and P-values
Stage II (n¼1143) Stage III (n¼1297) Stage IV (n¼1106) Stage unknown (n¼1204)
obs% adj% OR (95% CI) obs% adj% OR (95% CI) obs% adj% OR (95% CI) obs% adj% OR (95% CI)
Sex
Male 35 31 1 (ref) 45 43 1 (ref) 25 23 1 (ref) 26 19 1 (ref)
Female 27 24 0.72 (0.53, 0.97) 39 39 0.84 (0.65, 1.09) 20 20 0.84 (0.62, 1.16) 21 17 0.89 (0.65, 1.21)
P¼0.028 P¼0.193 P¼0.297 P¼0.452
Age
o55 48 46 1 (ref) 64 65 1 (ref) 33 32 1 (ref) 51 48 1 (ref)
55–64 42 41 0.81 (0.53, 1.25) 48 47 0.48 (0.33, 0.70) 27 26 0.77 (0.50, 1.18) 36 32 0.51 (0.31, 0.85)
65–74 36 35 0.62 (0.41, 0.94) 45 45 0.45 (0.31, 0.64) 24 24 0.66 (0.45, 0.97) 30 25 0.37 (0.23, 0.60)
75+ 13 11 0.15 (0.09, 0.24) 22 21 0.14 (0.09, 0.21) 14 13 0.33 (0.21, 0.53) 11 9 0.11 (0.07, 0.18)
Po0.001 Po0.001 Po0.001 Po0.001
Marital status
Married — 48 44 1 (ref) — —
Not married/
unknown
— 35 38 0.77 (0.60, 1.01) — —
P¼0.055
Tumour extent
T1 — 28 22 0.41 (0.16, 1.08) — 7 4 0.09 (0.04, 0.20)
T2 — 40 39 0.94 (0.66, 1.33) — 21 15 0.41 (0.22, 0.75)
T3 31 27 1 (ref) 43 41 1 (ref) — 40 31 1 (ref)
T4 42 39 1.70 (1.14, 2.53) 48 48 1.35 (0.93, 1.96) — 41 40 1.50 (0.88, 2.54)
Missing — 47 54 1.73 (0.56, 5.33) — 21 18 0.50 (0.33, 0.75)
P¼0.009 P¼0.124 Po0.001
Year of diagnosis 1.21 (1.15, 1.28) 1.19 (1.13, 1.25) 1.14 (1.08, 1.21) 1.21 (1.13, 1.29)
Po0.001 Po0.001 Po0.001 Po0.001
CI¼confidence interval; OR¼odds ratio.
aOdds ratios adjusted for factors shown in relevant columns. Stage II, III, and unknown stage disease are also adjusted for health board.
Stage IV and unknown stage disease are also adjusted for grade.
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here also; Yancik et al (1998) found that female patients were less
likely than male patients to have a high-impact life-threatening
co-morbid condition.
With regard to adjuvant treatment, we observed significant
disparities in use even after adjusting for stage and other clinical
factors. The increased likelihood of treatment in married patients
was also noted in a small chemotherapy study (Bouchardy et al,
2001). The explanation is not clear but possibilities include active
involvement of spouse/family members in care management,
spousal support (emotional and logistical) during treatment, and
different perceptions – by clinicians or patients – of the ‘value’ of
life in those with and without a spouse and/or dependants. Age was
the strongest predictor of receipt of chemotherapy or radio-
therapy. Although reported elsewhere (Faivre-Finn et al, 2000;
Schrag et al, 2001a,b; Cronin et al, 2006), this finding remains
important given that one-third of colorectal cancer patients are 75
or older. Although the higher prevalence of co-morbidities (Yancik
et al, 1998) may preclude treatment in some elderly patients, in the
United States the age effect persists even among those without co-
morbidities (Schrag et al, 2001a,b). Older patients may also have
increased treatment-related toxicity, although evidence on this is
mixed (Sargent et al, 2001). Both RCTs (Sargent et al, 2001) and
observational studies (Bouchardy et al, 2001; Schrag et al, 2001a;
Jessup et al, 2005) demonstrate clear survival benefits of adjuvant
chemotherapy in patients of all ages, suggesting that there may be
further potential for (and benefits to be gained from) extended use
in older patients in routine practice.
Randomised controlled trials suggest that chemotherapy may
benefit stage II colon patients with poor prognostic features (Gill
et al, 2004; Australian Cancer Network Colorectal Cancer Guide-
lines Revision Committee, 2005; Andre ´ et al, 2006). These findings
appear to have disseminated into routine practice, as those stage II
patients in our study with more extensive tumours were
significantly more likely to be treated.
Factors associated with mortality
Among surgical patients, risks of death decreased over time,
which may be partly due to reductions in post-operative
mortality (Faivre-Finn et al, 2002). The increased risk of
death with increasing age among surgical patients may also be a
function of post-operative mortality. In further analyses,
patients aged X75 were four times more likely to die in the
Table 4 Factors associated with risk of death among colorectal cancer
patients diagnosed during 1994–2002, stratified by receipt of surgery:
HRs,
a 95% CIs, and P-values
No surgery
b
(n¼3373)
Surgery
b
(n¼11876)
HR (95% CI) HR (95% CI)
Sex
Male 1.00 1.00
Female 0.90 (0.84, 0.98) 0.81 (0.77, 0.85)
P¼0.010 Po0.001
Age
o55 1.00 1.00
55–64 1.10 (0.94, 1.29) 1.12 (1.02, 1.23)
65–74 1.41 (1.22, 1.63) 1.42 (1.30, 1.55)
75+ 1.70 (1.47, 1.96) 2.16 (1.97, 2.37)
Po0.001 Po0.001
Stage
I 0.48 (0.32, 0.71) 0.36 (0.33, 0.40)
II 0.76 (0.58, 0.98) 0.58 (0.54, 0.62)
III 1.00 1.00
IV 2.31 (1.91, 2.78) 2.83 (2.64, 3.03)
Unknown 1.33 (1.10, 1.61) 0.69 (0.63, 0.76)
Po0.001 Po0.001
Marital status
Married 1.00 1.00
Not married/unknown 1.12 (1.04, 1.21) 1.12 (1.06, 1.18)
P¼0.005 Po0.001
Smoking status
Non-smoker/unknown 1.00 1.00
Current smoker 1.09 (1.00, 1.20) 1.14 (1.07, 1.22)
Ex-smoker 1.10 (0.99, 1.22) 1.03 (0.96, 1.10)
P¼0.061 Po0.001
Grade
Well 1.00 1.00
Moderate 0.94 (0.79, 1.13) 1.06 (0.97, 1.16)
Poor/undifferentiated 1.43 (1.17, 1.75) 1.40 (1.27, 1.56)
Missing 1.15 (0.96, 1.36) 1.12 (1.01, 1.25)
Po0.001 Po0.001
Period of diagnosis
1994–96 1.00
1997–99 — 0.87 (0.82, 0.92)
2000–02 0.82 (0.76, 0.87)
Po0.001
CI¼confidence interval; HR¼hazard ratio.
aAll HRs adjusted for factors shown in
relevant column (other than site), plus health board and site (colon/rectum).
bModels
also stratified by receipt of chemotherapy and radiotherapy.
Table 5 Risk of death by adjuvant treatment
a for colorectal cancers diagnosed during 1994–2002: HRs with 95% CIs
Stage II Stage III Stage IV Stage unknown
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Chemotherapy: colorectal cancer
All patients
b 0.88 (0.77, 1.01) 0.67 (0.61, 0.75) 0.83 (0.76, 0.91) 1.23 (1.03, 1.47)
Surgical patients
c 0.96 (0.84, 1.10) 0.69 (0.62, 0.76) 0.77 (0.68, 0.88) 1.57 (1.23, 2.00)
Radiotherapy: rectal cancer
All patients: any radiotherapy
d,e 1.23 (0.98, 1.55) 1.06 (0.90, 1.24) 0.97 (0.83, 1.14) 1.15 (0.94, 1.40)
Surgical patients: any radiotherapy
c,d 1.09 (0.88, 1.35) 0.88 (0.75, 1.04) 0.79 (0.62, 1.00) 1.41 (1.03, 1.94)
Surgical+radiotherapy patients:
pre-operative radiotherapy
f
1.03 (0.63, 1.66) 0.61 (0.42, 0.91) 0.70 (0.40, 1.25) 0.60 (0.36, 1.02)
CI¼confidence interval; HR¼hazard ratio.
aTreatment received within 1 year of diagnosis.
bHazard ratios adjusted for age, sex, marital status, smoking status, health board,
tumour extent (T), nodes (N), site, surgery receipt (yes/no), and radiotherapy (time-dependant covariate).
cHazard ratios adjusted for age, sex, marital status, smoking status,
health board, tumour extent (T), nodes (N), and site.
dPre- or post-operative radiotherapy vs no radiotherapy.
eHazard ratios adjusted for age, sex, marital status, smoking status,
health board, tumour extent (T), nodes (N), surgery receipt (yes/no), and chemotherapy (time-dependant covariate).
fComparison of pre- vs post-operative radiotherapy among
patients treated with surgery and radiotherapy; HR adjusted for age, sex, marital status, smoking status, health board, tumour extent (T), and nodes (N).
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95% CI 2.46–6.59).
The increased hazard in those who were smokers at diagnosis
is intriguing. As smoking status is based on information recorded
in medical records, misclassification is probable, but it is
most likely that some smokers would have been categorized as
non-smokers rather than the other way; thus, the observed
result probably underestimates the true effect. The finding does
not seem to be due to deaths from other causes in smokers, as the
association persisted when cause-specific mortality was analysed.
Two small studies have reported poorer outcomes in
smokers following colorectal cancer surgery (Jadallah et al, 1999;
Munro et al, 2006). Although the result could be due to
confounding by another prognostic factor such as deprivation
(Bouchardy et al, 2001; Pitchforth et al, 2002; Wrigley et al, 2003),
there are several potential mechanisms by which smoking
might adversely affect survival. These include effects on
immune function (O’Byrne et al, 2000), inflammatory response
(Yanbaeva et al, 2007), metabolism of chemotherapy drugs
(van der Bol et al, 2007), and genetic damage and repair capacity
(Fracasso et al, 2006).
Treatment, survival, and mortality
We investigated the impact of treatment on mortality and survival
primarily to determine whether the advances seen in RCTs
have translated into improvements for the entire patient
population. Clearly, survival comparisons in an observational
study are potentially subject to bias and will tend to favour
treatment (because of the selection of patients with
better prognostic features for treatment). Although the intro-
duction of time-varying covariates, and adjustment for other
factors, would be expected to attenuate the bias somewhat, we
cannot exclude the possibility that our results are influenced by
unmeasured confounders. The Kaplan–Meier survival curves may
be particularly susceptible in this regard, as they are adjusted for
age only.
Given the controversy around resection of the primary tumour
in stage IV patients, our observations of lower mortality and longer
survival among resected patients at the population-level are
noteworthy. In particular, the survival advantage conferred by
the combination of chemotherapy and surgery is important and
compatible with RCT evidence on prolonged survival for advanced
patients treated with palliative chemotherapy (Colorectal Cancer
Collaborative Group, 2000b). Similar results have recently been
reported in the US population-based studies (Temple et al, 2004;
Cook et al, 2005) and clinical series (Ruo et al, 2003; Konyalian
et al, 2007). Given that stage IV disease is not uncommon
(it accounted for more than one-fifth of our cases), the role
of resection of the primary tumour (in combination with
chemotherapy) warrants further investigation. Issues such as
impact of treatment on quality of life need to be addressed.
The higher survival and significant mortality reduction for stage
III patients receiving chemotherapy at the population level is
consistent with evidence of survival benefits for colon cancer from
RCTs (Andre ´ et al, 2004a). The lack of a survival advantage for
chemotherapy among stage II patients overall is also compatible
with RCT evidence which suggests that the survival improvement,
if any, is small (Benson et al, 2004; Andre ´ and de Gramont, 2004b).
As we were not able to clearly distinguish stage II patients with
particularly poor prognostic features, we cannot exclude a
beneficial effect of treatment at the population level in this
subgroup.
Although post-operative radiotherapy has been relatively
long established as the standard of care for rectal cancer, we
found no clear benefit in terms of survival or mortality at the
population level in stage II–III patients. This is consistent with a
systematic review of 22 RCTs, which concluded that the impact on
survival was marginal (Colorectal Cancer Collaborative Group,
2001). In the current study, risk of death was decreased when
radiotherapy was administered pre-operatively although the
findings were based on small numbers and were not statistically
significant for stage II disease. Although RCTs suggest that pre-
operative radiotherapy reduces rectal cancer deaths, this appears
to be at the cost of increased risk of death from other causes
(Colorectal Cancer Collaborative Group, 2001). Our results, based
on deaths from all causes, suggest that advantages may outweigh
disadvantages at the population level, at least for patients
diagnosed with stage III disease.
As has been observed elsewhere (Verdecchia et al, 2007),
colorectal cancer survival in Ireland is rising (Walsh and Comber,
2007). As the proportion of early-stage tumours did not increase
over time and no screening is in place, it is unlikely that this
improvement is due to earlier detection. Instead it may reflect the
increased use of (neo-) adjuvant treatment that we have shown
here – as well as other treatment-related factors such as
advancements in surgical techniques, increased specialization,
and so on. Despite the improvement, survival in Ireland remains
below US figures and the EU average (Verdecchia et al, 2007).
Although these differences are probably due in part to stage (Gatta
et al, 2000), the relatively lower rates of cancer-directed treatment
that we describe probably play a role.
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Figure 2 Kaplan–Meier survival curves (adjusted for age) by receipt of treatment: colorectal cancer.
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sCONCLUSIONS
While recognizing that not all patients are suitable candidates for surgery
or (neo-)adjuvant therapy, our findings suggest that there is potential for
extended dissemination of therapies in routine clinical practice – both
overall and in particular patient subgroups. Improving treatment
availability generally, and equity specifically, has the potential to increase
survival and ultimately reduce mortality at the population level.
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